Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

BACKGROUND: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19. METHODS: In this phase 3, double-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Marconi, Vincent C, Ramanan, Athimalaipet V, de Bono, Stephanie, Kartman, Cynthia E, Krishnan, Venkatesh, Liao, Ran, Piruzeli, Maria Lucia B, Goldman, Jason D, Alatorre-Alexander, Jorge, de Cassia Pellegrini, Rita, Estrada, Vicente, Som, Mousumi, Cardoso, Anabela, Chakladar, Sujatro, Crowe, Brenda, Reis, Paulo, Zhang, Xin, Adams, David H, Ely, E Wesley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409066/
https://www.ncbi.nlm.nih.gov/pubmed/34480861
http://dx.doi.org/10.1016/S2213-2600(21)00331-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409066/
https://www.ncbi.nlm.nih.gov/pubmed/34480861
http://dx.doi.org/10.1016/S2213-2600(21)00331-3

Ejemplares similares